B-ALL
MCID: BLY001
MIFTS: 48

B-Lymphoblastic Leukemia/lymphoma (B-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for B-Lymphoblastic Leukemia/lymphoma

MalaCards integrated aliases for B-Lymphoblastic Leukemia/lymphoma:

Name: B-Lymphoblastic Leukemia/lymphoma 12 15 37
Precursor B Lymphoblastic Lymphoma/leukemia 12
B Lymphoblastic Leukemia/lymphoma 6
B-All 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080630
NCIt 49 C8936
UMLS 71 C0862030

Summaries for B-Lymphoblastic Leukemia/lymphoma

Disease Ontology : 12 A B-cell acute lymphoblastic leukemia that is characterized by the presence of too many B-cell lymphoblasts in the blood and bone marrow.

MalaCards based summary : B-Lymphoblastic Leukemia/lymphoma, also known as precursor b lymphoblastic lymphoma/leukemia, is related to b-lymphoblastic leukemia/lymphoma with hypodiploidy and b-lymphoblastic leukemia/lymphoma with hyperdiploidy. An important gene associated with B-Lymphoblastic Leukemia/lymphoma is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Teniposide and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and b lymphoblasts, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for B-Lymphoblastic Leukemia/lymphoma

Diseases related to B-Lymphoblastic Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma with hypodiploidy 34.4 TCF3 RET CEBPA APC
2 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 33.4 TCF3 RET MSH2 MAP2K2 BRCA2 APC
3 leukemia, acute lymphoblastic 31.3 TCF3 RB1 PTPN11 MYC MSH2 KIT
4 lymphoblastic lymphoma 29.2 ZMYM2 MYC FGFR1
5 myeloproliferative neoplasm 29.1 ZMYM2 PTPN11 KIT FGFR1
6 retinoblastoma 29.1 RB1 MYC CEBPA BRCA2 APC
7 leukemia 28.9 TCF3 RB1 PTPN11 MYC KIT FGFR1
8 leukemia, chronic lymphocytic 28.5 PTPN11 MYC KIT CD19 BRCA2 APC
9 leukemia, chronic myeloid 28.1 PTPN11 MYC KIT FGFR1 CD19 ALK
10 sarcoma 28.0 RET RB1 MYC MSH2 KIT FGFR1
11 leukemia, acute myeloid 27.3 TCF3 PTPN11 MYC KIT FGFR1 CEBPA
12 lymphoma 27.0 ZMYM2 RB1 PTPN11 MYC MSH6 MSH2
13 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 13.1
14 b-lymphoblastic leukemia/lymphoma with iamp21 13.1
15 b-lymphoblastic leukemia/lymphoma with bcr-abl1 13.0
16 b-lymphoblastic leukemia/lymphoma kmt2a rearranged 13.0
17 b-lymphoblastic leukemia/lymphoma with etv6-runx1 13.0
18 b-lymphoblastic leukemia/lymphoma with il3-igh 13.0
19 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 13.0
20 t-cell acute lymphoblastic leukemia 11.4
21 leukemia, acute lymphoblastic 3 10.7
22 periampullary adenoma 10.5 MSH6 APC
23 extrahepatic bile duct adenoma 10.5 MSH6 MSH2
24 renal pelvis transitional cell carcinoma 10.5 MSH6 MSH2
25 adenosquamous colon carcinoma 10.5 MSH6 MSH2
26 familial colorectal cancer 10.5 MSH2 APC
27 appendix carcinoid tumor 10.5 MSH6 MSH2
28 noonan syndrome and noonan-related syndrome 10.5 PTPN11 MAP2K2
29 jejunal cancer 10.4 MSH6 MSH2
30 anaplastic/large cell medulloblastoma 10.4 BRCA2 ALK
31 myh-associated polyposis 10.4 MSH2 APC
32 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.4 KIT CEBPA
33 attenuated familial adenomatous polyposis 10.4 MSH6 MSH2 APC
34 skin granular cell tumor 10.4 PTPN11 MAP2K2
35 colorectal cancer, hereditary nonpolyposis, type 5 10.3 MSH6 MSH2 APC
36 colorectal cancer, hereditary nonpolyposis, type 6 10.3 MSH6 MSH2
37 dysplastic nevus syndrome 10.3 MSH6 MSH2 BRCA2
38 testicular spermatocytic seminoma 10.3 RET PTPN11
39 breast-ovarian cancer, familial 1 10.3 MSH6 MSH2 BRCA2
40 female reproductive endometrioid cancer 10.3 MSH6 MSH2 BRCA2
41 mismatch repair cancer syndrome 10.3 MSH6 MSH2 APC
42 juvenile polyposis syndrome 10.3 MSH6 MSH2 APC
43 legius syndrome 10.3 PTPN11 MSH6 MSH2
44 autosomal dominant non-syndromic intellectual disability 8 10.3 MSH6 MSH2
45 small intestine leiomyoma 10.3 PTCH1 KIT
46 esophageal atresia/tracheoesophageal fistula 10.3 TEF BRCA2
47 down syndrome 10.3
48 follicular lymphoma 10.3
49 b-cell lymphoma 10.3
50 chromosomal triplication 10.3

Graphical network of the top 20 diseases related to B-Lymphoblastic Leukemia/lymphoma:



Diseases related to B-Lymphoblastic Leukemia/lymphoma

Symptoms & Phenotypes for B-Lymphoblastic Leukemia/lymphoma

GenomeRNAi Phenotypes related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.89 ALK FGFR1 KIT MYC RET
2 Decreased viability GR00221-A-2 9.89 FGFR1 RET
3 Decreased viability GR00221-A-3 9.89 MYC
4 Decreased viability GR00221-A-4 9.89 ALK RET
5 Decreased viability GR00249-S 9.89 ALK MYC
6 Decreased viability GR00301-A 9.89 KIT RET
7 Decreased viability GR00386-A-1 9.89 FGFR1
8 Decreased viability GR00402-S-2 9.89 MYC RET
9 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 APC BRCA2 MAP2K2 MSH2 PTPN11

MGI Mouse Phenotypes related to B-Lymphoblastic Leukemia/lymphoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 APC BRCA2 CD19 CEBPA FGFR1 KIT
2 homeostasis/metabolism MP:0005376 10.5 ALK APC BRCA2 CD19 CEBPA FGFR1
3 behavior/neurological MP:0005386 10.48 ALK APC BRCA2 CD19 CEBPA FGFR1
4 mortality/aging MP:0010768 10.46 ALK APC BRCA2 CD19 CEBPA FGFR1
5 growth/size/body region MP:0005378 10.44 ALK APC BRCA2 CD19 CEBPA FGFR1
6 digestive/alimentary MP:0005381 10.42 APC BRCA2 CD19 CEBPA FGFR1 KIT
7 hematopoietic system MP:0005397 10.42 APC BRCA2 CD19 CEBPA FGFR1 KIT
8 cardiovascular system MP:0005385 10.41 APC CD19 CEBPA FGFR1 KIT MAP2K2
9 endocrine/exocrine gland MP:0005379 10.41 ALK APC BRCA2 CEBPA FGFR1 KIT
10 immune system MP:0005387 10.4 APC BRCA2 CD19 CEBPA FGFR1 KIT
11 integument MP:0010771 10.39 ALK APC BRCA2 CD19 CEBPA FGFR1
12 neoplasm MP:0002006 10.35 ALK APC BRCA2 CD19 CEBPA KIT
13 embryo MP:0005380 10.3 APC BRCA2 FGFR1 KIT MYC PTCH1
14 nervous system MP:0003631 10.3 ALK APC BRCA2 CD19 FGFR1 KIT
15 limbs/digits/tail MP:0005371 10.24 APC BRCA2 FGFR1 KIT MYC PTCH1
16 craniofacial MP:0005382 10.22 APC FGFR1 KIT MAP2K2 MYC PTCH1
17 normal MP:0002873 10.22 APC BRCA2 CD19 CEBPA FGFR1 KIT
18 hearing/vestibular/ear MP:0005377 10.19 APC FGFR1 KIT MAP2K2 MYC PTCH1
19 liver/biliary system MP:0005370 10.18 APC CD19 CEBPA KIT MYC PTPN11
20 muscle MP:0005369 10.15 APC CEBPA FGFR1 KIT MYC PTCH1
21 no phenotypic analysis MP:0003012 10.09 CEBPA FGFR1 KIT MYC PTCH1 PTPN11
22 reproductive system MP:0005389 10.03 ALK APC BRCA2 CEBPA FGFR1 KIT
23 renal/urinary system MP:0005367 9.97 APC CD19 CEBPA FGFR1 KIT PTCH1
24 pigmentation MP:0001186 9.91 ALK APC KIT MYC PTCH1 PTPN11
25 respiratory system MP:0005388 9.7 ALK CEBPA KIT PTCH1 PTPN11 RB1
26 skeleton MP:0005390 9.65 ALK APC BRCA2 FGFR1 KIT MAP2K2
27 vision/eye MP:0005391 9.28 ALK APC CEBPA FGFR1 KIT MAP2K2

Drugs & Therapeutics for B-Lymphoblastic Leukemia/lymphoma

Drugs for B-Lymphoblastic Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 366)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Ethanol Approved Phase 4 64-17-5 702
6
Methadone Approved Phase 4 76-99-3 4095
7
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
8
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
9
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
rituximab Approved Phase 4 174722-31-7 10201696
12
leucovorin Approved Phase 4 58-05-9 6006 143
13
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15 Estradiol 17 beta-cypionate Phase 4
16 Estradiol 3-benzoate Phase 4
17 Estrogens Phase 4
18 Progestins Phase 4
19 Respiratory System Agents Phase 4
20 Narcotics Phase 4
21 Analgesics, Opioid Phase 4
22 Antitubercular Agents Phase 4
23 Antitussive Agents Phase 4
24 Lipid Regulating Agents Phase 4
25 Narcotic Antagonists Phase 4
26 Hypolipidemic Agents Phase 4
27 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
28 Immunosuppressive Agents Phase 4
29 Immunologic Factors Phase 4
30 Antineoplastic Agents, Immunological Phase 4
31 Vitamin B Complex Phase 4
32 Folate Phase 4
33 Dermatologic Agents Phase 4
34 Folic Acid Antagonists Phase 4
35 Antimetabolites Phase 4
36 Vitamin B9 Phase 4
37
Norgestrel Approved Phase 2, Phase 3 6533-00-2 13109
38
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
39
Hydroxyurea Approved Phase 3 127-07-1 3657
40
Interferon beta-1b Approved Phase 3 145155-23-3
41
Melphalan Approved Phase 3 148-82-3 460612 4053
42
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
43
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
44
Repaglinide Approved, Investigational Phase 3 135062-02-1 65981
45
Nateglinide Approved, Investigational Phase 3 105816-04-4 60026
46
Glimepiride Approved Phase 3 93479-97-1 3476
47
Gliclazide Approved Phase 3 21187-98-4 3475
48
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
49
Miglitol Approved Phase 3 72432-03-2 441314
50
Glyburide Approved Phase 3 10238-21-8 3488

Interventional clinical trials:

(show top 50) (show all 263)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
5 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
6 Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone Completed NCT01940653 Phase 4 Progesterone
7 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
8 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
9 Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation Suspended NCT00502281 Phase 4 highly purified urinary FSH
10 Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study) Terminated NCT01117129 Phase 4 rituximab [MabThera/Rituxan];placebo;methotrexate;rituximab [Mabthera/Rituxan]
11 Is Early Preparation With GnRh Agonists Injection on D-1 of Menses of Hormonal Replacement Cycle Improves Pregnancy Rate in Women With Impaired Ovulation and Undergoing Frozen-Thawed Embryo Transfer? A Randomized Controlled Study Unknown status NCT03353883 Phase 2, Phase 3 Triptorelin SR
12 A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopan™) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis. Unknown status NCT01854476 Phase 2, Phase 3
13 PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
14 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
15 International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg Completed NCT00459667 Phase 3 Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046)
16 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
17 BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B Completed NCT01488994 Phase 2, Phase 3
18 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
19 Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-blind, Randomized, Active-controlled, Multicentre Study Completed NCT00838214 Phase 2, Phase 3 budesonide;prednisone
20 A Phase III, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of Addition of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Oral Antihyperglycemic Agent Monotherapy Completed NCT01697592 Phase 3 Omarigliptin;Matching placebo to omarigliptin
21 Effect of Preoperative, Single-dose Diclofenac Potassium on Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis: A Double Blind Randomized Controlled Trial Completed NCT03341260 Phase 2, Phase 3 Diclofenac Potassium 50mg Tab.;Placebo
22 A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old. Completed NCT00443235 Phase 3 Melphalan/Prednisone/Velcade;Thalidomide/Prednisone/Velcade
23 Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS) Completed NCT01077960 Phase 3
24 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
25 Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma Completed NCT00052923 Phase 3 carmustine;cyclophosphamide;etoposide
26 Circadian Variation in Cytokines and the Effect of Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
27 General Surgery Residents Education in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Simulation-Based Training Completed NCT00787345 Phase 3
28 A Multicentre, Multinational Study of Oral Vitamin K for the Treatment of Warfarin Associated Coagulopathy Completed NCT00143715 Phase 3 Phytonadione (Vitamin K1)
29 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine;Vincristine Sulfate
30 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
31 A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Recruiting NCT03575351 Phase 3 Standard of Care
32 A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine;Vincristine Sulfate
33 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine;Thioguanine
34 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
35 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
36 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
37 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Active, not recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
38 Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
39 An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic Clonic Seizures Active, not recruiting NCT02849626 Phase 3 Perampanel
40 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
41 A Pilot Study Comparing Intra-articular Corticosteroid Injections to Platelet Rich Plasma (PRP) as a Treatment for Cervical Facetogenic Pain Not yet recruiting NCT04392999 Phase 2, Phase 3 Intraarticular platelet rich plasma cervical facet injection;Corticosteroid injection
42 SPondyloArthritis: Inducing Drug-free Remission by Early TNF-Alpha bloCkade Under Guidance of Single Cell RNA Sequencing and Epigenetic Profiling. "The SPARTACUS Trial" Not yet recruiting NCT04435288 Phase 3 week 24;week 36;Week 48;Week 60
43 Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B Terminated NCT01369199 Phase 3 Entecavir and peginterferon
44 A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer. Terminated NCT02144012 Phase 3 Trastuzumab;Trastuzumab Emtansine;Docetaxel
45 Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients Unknown status NCT03142646 Phase 1, Phase 2
46 The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study Unknown status NCT02334163 Phase 2 Nitazoxanide;Oral lactulose;Metronidazole;Rifaximine
47 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus Unknown status NCT02850601 Phase 2 Dexamethasone
48 A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride Completed NCT00289562 Phase 1, Phase 2 forodesine hydrochloride (BCX-1777)
49 A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00807495 Phase 2 Alisertib
50 Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy Completed NCT00324779 Phase 2

Search NIH Clinical Center for B-Lymphoblastic Leukemia/lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Lymphoblastic Leukemia/lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for B-Lymphoblastic Leukemia/lymphoma:
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to B-Lymphoblastic Leukemia/lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for B-Lymphoblastic Leukemia/lymphoma

Anatomical Context for B-Lymphoblastic Leukemia/lymphoma

MalaCards organs/tissues related to B-Lymphoblastic Leukemia/lymphoma:

40
B Cells, T Cells, B Lymphoblasts, Bone, Breast, Prostate, Bone Marrow

Publications for B-Lymphoblastic Leukemia/lymphoma

Articles related to B-Lymphoblastic Leukemia/lymphoma:

(show top 50) (show all 70)
# Title Authors PMID Year
1
Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases. 61
32540222 2020
2
Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis. 61
32068791 2020
3
Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. 61
32302940 2020
4
Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. 61
31705772 2020
5
Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts. 61
32191803 2020
6
Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT+ B-lymphoblastic leukemia/lymphoma. 61
31776129 2020
7
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients. 61
31197916 2020
8
Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. 61
31575852 2019
9
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use. 61
30938769 2019
10
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
31261288 2019
11
B-lymphoblastic leukemia/lymphoma with an unusual appendiceal involvement. 61
31558557 2019
12
Histiocytic Sarcoma Following B-Lymphoblastic Leukemia/Lymphoma. 61
31172191 2019
13
Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. 61
31272582 2019
14
BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies. 61
31069976 2019
15
Immature Terminal Deoxynucleotidyl Transferase Positive B Cells are Detected in a Subset of Adult and Pediatric Liver Biopsies. 61
28968264 2019
16
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. 61
30181564 2019
17
[Clinicopathologic features of breast lymphoma in core needle biopsy]. 61
30317726 2018
18
Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma. 61
29696694 2018
19
Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia. 61
29501750 2018
20
B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients. 61
29112016 2018
21
Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma. 61
29336635 2018
22
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. 61
27598971 2018
23
Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation. 61
29140408 2017
24
B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy. 61
29029550 2017
25
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency. 61
32300395 2017
26
Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement. 61
26517296 2017
27
CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma. 61
28032275 2017
28
Chronic Myelogenous Leukemia Presenting as a Secondary Malignancy After BCR-ABL1-negative B-lymphoblastic Leukemia/Lymphoma in a Pediatric Patient. 61
28276292 2017
29
Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges. 61
26892631 2016
30
CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients. 61
28430957 2016
31
CD10 expression in the neuroendocrine carcinoma component of endometrial mixed carcinoma: association with long survival. 61
26830028 2016
32
Blindsided by the Monospot test. 61
29540032 2015
33
B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. 61
25873506 2015
34
Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. 61
25529125 2015
35
B-lymphoblastic leukemia/lymphoma: overexpression of nuclear DNA repair protein PARP-1 correlates with antiapoptotic protein Bcl-2 and complex chromosomal abnormalities. 61
24856976 2014
36
Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. 61
24589157 2014
37
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. 61
24619868 2014
38
Monocytopenia as a diagnostic clue to pediatric B-lymphoblastic leukemia with rare circulating blasts. 61
24804826 2014
39
B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. 61
30107017 2013
40
[An autopsy case of B lymphoblastic leukemia/lymphoma with hemophagocytic syndrome infiltrating in the central nervous systems]. 61
24218764 2013
41
Characterization of a case of follicular lymphoma transformed into B-lymphoblastic leukemia. 61
23985173 2013
42
Monocytopenia as a diagnostic clue to pediatric B-lymphoblastic leukemia with rare circulating blasts. 61
23815676 2013
43
Concurrent t(4;11) and t(1:19) in a Pediatric Patient with B-Lymphoblastic Leukemia/Lymphoma (B-ALL): A Case Report and Review of the Literature. 61
26030419 2013
44
B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature. 61
23594707 2013
45
Advances in the molecular pathobiology of B-lymphoblastic leukemia. 61
22575265 2012
46
[Overview of lymphoid neoplasms in the fourth edition of the WHO classification]. 61
22880234 2012
47
Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. 61
22372201 2012
48
Double-hit lymphoma with a feature of follicular lymphoma concurrent with clonally related B lymphoblastic leukemia : a preference of transformation for the bone marrow. 61
23037627 2012
49
De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13. 61
21718139 2011
50
Quantitative real time PCR analysis of apoptosis-related gene expression in leukemias in Ukrainian patients. 61
21716208 2011

Variations for B-Lymphoblastic Leukemia/lymphoma

ClinVar genetic disease variations for B-Lymphoblastic Leukemia/lymphoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CDH1 NM_004360.5(CDH1):c.1865A>G (p.Asn622Ser)SNV Uncertain significance 136062 rs147925149 16:68856057-68856057 16:68822154-68822154

Expression for B-Lymphoblastic Leukemia/lymphoma

Search GEO for disease gene expression data for B-Lymphoblastic Leukemia/lymphoma.

Pathways for B-Lymphoblastic Leukemia/lymphoma

Pathways related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 TCF3 RB1 PTCH1 MYC MAP2K2 KIT
2
Show member pathways
13.43 TCF3 RET PTPN11 MAP2K2 KIT FGFR1
3
Show member pathways
12.87 RB1 MYC MAP2K2 KIT FGFR1 CD19
4
Show member pathways
12.62 RB1 MYC MSH6 MSH2 BRCA2
5
Show member pathways
12.58 RB1 MYC MAP2K2 KIT FGFR1 BRCA2
6
Show member pathways
12.55 RB1 MSH6 MAP2K2 FGFR1 BRCA2 ALK
7
Show member pathways
12.48 RET RB1 PTPN11 MYC MSH6 MSH2
8 12.45 RB1 MSH6 MSH2 BRCA2
9 12.36 TCF3 RB1 MYC APC
10
Show member pathways
12.34 PTPN11 MYC MAP2K2 CD19
11
Show member pathways
12.33 PTPN11 MYC MAP2K2 CEBPA
12
Show member pathways
12.32 MAP2K2 KIT FGFR1 APC ALK
13 12.26 TCF3 RB1 MYC MAP2K2
14 12.22 PTPN11 PTCH1 MYC MAP2K2 FGFR1
15
Show member pathways
12.17 RB1 PTPN11 MYC KIT FGFR1
16 12.16 RET RB1 PTCH1 MYC MSH6 MSH2
17 12.04 RET KIT FGFR1 ALK
18 12.04 RB1 MYC MSH6 MSH2 BRCA2
19 11.99 TCF3 MYC MAP2K2 FGFR1 APC
20 11.85 TCF3 MYC MSH6 MSH2 MAP2K2 APC
21
Show member pathways
11.84 PTPN11 MYC MAP2K2
22 11.82 KIT CEBPA CD19
23 11.78 RB1 MYC MSH6
24
Show member pathways
11.77 PTPN11 MYC MAP2K2
25
Show member pathways
11.76 RET MAP2K2 KIT FGFR1
26 11.76 TCF3 RB1 MYC MAP2K2 APC
27
Show member pathways
11.74 RB1 MSH6 MSH2 BRCA2
28 11.71 MYC KIT CEBPA
29 11.68 RB1 MYC CEBPA
30 11.67 RB1 MYC MAP2K2
31 11.61 MYC MAP2K2 CEBPA
32 11.5 TCF3 MYC APC
33 11.5 RET MYC MAP2K2 KIT FGFR1
34 11.45 RET RB1 MYC
35 11.43 PTPN11 MYC MAP2K2
36 11.39 MYC MAP2K2 FGFR1
37 11.37 RB1 MYC MSH6 MSH2
38 11.29 RB1 MYC BRCA2
39
Show member pathways
11.16 PTPN11 MYC MAP2K2

GO Terms for B-Lymphoblastic Leukemia/lymphoma

Cellular components related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 ZMYM2 TEF TCF3 RB1 PTPN11 PTCH1
2 receptor complex GO:0043235 9.46 RET KIT FGFR1 ALK
3 mismatch repair complex GO:0032300 9.26 MSH6 MSH2
4 MutSalpha complex GO:0032301 8.62 MSH6 MSH2

Biological processes related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.08 ZMYM2 TEF RB1 MYC KIT CEBPA
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.05 TCF3 RB1 PTCH1 MYC FGFR1 CEBPA
3 protein phosphorylation GO:0006468 10.04 RET MAP2K2 KIT FGFR1 ALK
4 cellular response to DNA damage stimulus GO:0006974 10 MYC MSH6 MSH2 BRCA2 APC
5 negative regulation of gene expression GO:0010629 9.94 RB1 MYC MAP2K2 FGFR1
6 cytokine-mediated signaling pathway GO:0019221 9.93 PTPN11 MYC KIT CEBPA
7 in utero embryonic development GO:0001701 9.88 PTCH1 MYC MSH2 FGFR1
8 brain development GO:0007420 9.85 PTPN11 PTCH1 FGFR1 BRCA2 ALK
9 MAPK cascade GO:0000165 9.83 RET MYC MAP2K2 KIT FGFR1
10 cell cycle arrest GO:0007050 9.8 RB1 MYC MSH2 APC
11 B cell differentiation GO:0030183 9.79 TCF3 MSH2 KIT
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.78 RET KIT FGFR1 ALK
13 regulation of cell proliferation GO:0042127 9.77 PTCH1 KIT FGFR1 CEBPA ALK
14 regulation of mitotic cell cycle GO:0007346 9.71 RB1 PTCH1 MYC MAP2K2
15 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.7 MSH6 MSH2 BRCA2
16 somatic hypermutation of immunoglobulin genes GO:0016446 9.65 MSH6 MSH2
17 positive regulation of protein kinase B signaling GO:0051897 9.65 RET PTPN11 KIT FGFR1 CD19
18 neuron maturation GO:0042551 9.63 RET RB1
19 positive regulation of pseudopodium assembly GO:0031274 9.62 KIT APC
20 positive regulation of phospholipase C activity GO:0010863 9.62 KIT FGFR1
21 positive regulation of kinase activity GO:0033674 9.62 RET KIT FGFR1 ALK
22 negative regulation of cell division GO:0051782 9.59 PTCH1 MYC
23 positive regulation of helicase activity GO:0051096 9.57 MSH6 MSH2
24 maintenance of DNA repeat elements GO:0043570 9.56 MSH6 MSH2
25 chordate embryonic development GO:0043009 9.55 FGFR1 BRCA2
26 peptidyl-tyrosine phosphorylation GO:0018108 9.55 RET MAP2K2 KIT FGFR1 ALK
27 somatic recombination of immunoglobulin gene segments GO:0016447 9.54 MSH6 MSH2
28 B cell mediated immunity GO:0019724 9.51 MSH2 CD19
29 activation of MAPK activity GO:0000187 9.35 RET PTPN11 MAP2K2 KIT ALK
30 positive regulation of transcription, DNA-templated GO:0045893 9.23 TCF3 RET RB1 PTCH1 MYC MAP2K2

Molecular functions related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 ZMYM2 TEF TCF3 RET RB1 PTPN11
2 ATP binding GO:0005524 10.07 RET MSH6 MSH2 MAP2K2 KIT FGFR1
3 protein homodimerization activity GO:0042803 9.91 TCF3 MSH6 MSH2 KIT FGFR1 CEBPA
4 protein kinase activity GO:0004672 9.89 RET MAP2K2 KIT FGFR1 ALK
5 double-stranded DNA binding GO:0003690 9.62 TEF MYC MSH6 MSH2
6 mismatched DNA binding GO:0030983 9.51 MSH6 MSH2
7 MutLalpha complex binding GO:0032405 9.48 MSH6 MSH2
8 oxidized purine DNA binding GO:0032357 9.46 MSH6 MSH2
9 guanine/thymine mispair binding GO:0032137 9.4 MSH6 MSH2
10 single guanine insertion binding GO:0032142 9.37 MSH6 MSH2
11 single thymine insertion binding GO:0032143 9.26 MSH6 MSH2
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 RET KIT FGFR1 ALK
13 protein tyrosine kinase activity GO:0004713 9.02 RET MAP2K2 KIT FGFR1 ALK

Sources for B-Lymphoblastic Leukemia/lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....